Drug Information

Drug General Information
Drug ID
D0J6DQ
Former ID
DNCL002655
Drug Name
Tremelimumab
Drug Type
Monoclonal antibody
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 3 [525318], [543152]
Company
AstraZeneca
CAS Number
CAS 745013-59-6
Target and Pathway
Target(s) Cytotoxic T-lymphocyte protein 4 Target Info Modulator [543700]
KEGG Pathway Cell adhesion molecules (CAMs)
T cell receptor signaling pathway
Autoimmune thyroid disease
Rheumatoid arthritis
Pathway Interaction Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Reactome CTLA4 inhibitory signaling
WikiPathways Vitamin D Receptor Pathway
T-Cell Receptor and Co-stimulatory Signaling
Allograft Rejection
Costimulation by the CD28 family
References
Ref 525318ClinicalTrials.gov (NCT02551159) Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN.
Ref 543152(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8462).
Ref 543700(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.